Hormonal
Use of GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) is associated with a low incidence (1.18%) of psychiatric adverse events, including depression, anxiety, and suicidal ideation, with a small but significant number of fatal outcomes.
If you are taking semaglutide, liraglutide, or tirzepatide, be aware that mood changes like depression, anxiety, or suicidal thoughts are possible, though uncommon (approx 1%). Monitor your mental health closely. If you experience these symptoms, report them to your doctor immediately. Do not suffer in silence; early reporting helps manage safety risks.
There were 372 reports with psychiatric adverse event reports (n = 372; 1.18%) with a total of 481 adverse events... Depression was the most commonly reported adverse event (n = 187; 50.3%), followed by anxiety (n = 144; 38.7%) and suicidal ideation (n = 73; 19.6%).
Why this rating
Spontaneous reporting databases are subject to underreporting and bias, but the large volume of data (31k+ reports) provides signal detection capability.
Source
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
Mansour Tobaiqy et al. · International Journal of Clinical Pharmacy · 2024
DOI 10.1007/s11096-023-01694-7
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →